Last reviewed · How we verify
NCT05203276
Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC
Phase 2 trial testing Envafolimab in Lung Neoplasms in 40 participants. Status unknown.
30 May 2024
Quick facts
| Lead sponsor | The First People's Hospital of Lianyungang |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 1 March 2022 |
| Primary completion | 30 May 2024 |
| Estimated completion | 30 June 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Envafolimab — full drug profile →
- Endostar — full drug profile →
Conditions studied
- Lung Neoplasms — all drugs for Lung Neoplasms →
Sponsor
The First People's Hospital of Lianyungang
Who can join
Adults 18 to 80, any sex, with Lung Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the efficacy and safety of envafolimab combined with endostar in the first-line treatment of advanced Non-small Cell Lung Cancer With PD-L1 positive expression
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05203276
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Envafolimab
Trials testing the same drug.
- NCT06959693 — A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients Wit · Phase 2, PHASE3 · not yet recruiting
- NCT06692491 — Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS · Phase 2 · not yet recruiting
- NCT07260305 — A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolima · Phase 1 · recruiting
- NCT06618391 — Local Injection and Systemic Therapy in the Treatment of NSCLC. · Phase 2 · not yet recruiting
- NCT06663007 — RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure · Phase 1, PHASE2 · recruiting
Other recruiting trials for Lung Neoplasms
Currently open trials in the same condition.
- NCT07476287 — Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult · Phase 2 · recruiting
- NCT07509333 — MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients · NA · recruiting
- NCT07109154 — DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First- · recruiting
- NCT06974604 — Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM · Phase 2 · recruiting
- NCT07165691 — TELEhealth Shared Decision-making COaching for Lung Cancer Screening in Primary Care (TELESCOPE) for Hispanics · NA · recruiting
Other The First People's Hospital of Lianyungang trials
Trials by the same sponsor.
- NCT07481006 — Association Between Intraoperative Mean Arterial Pressure Variability and Postoperative Fatigue in Patients Undergoing L · not yet recruiting
- NCT07323043 — Comparison of Cough Response Between Tegilidine and Sufentanil as Pre-induction Agents in General Anesthesia · NA · recruiting
- NCT07279051 — Modified Mini-Open TLIF vs Traditional Open TLIF · NA · not yet recruiting
- NCT07096115 — ED90 of Teglidine for Suppressing LMA Insertion Response in the Elderly · NA · not yet recruiting
- NCT07081477 — Ciprofol's Influence on LVOT VTI in Elderly Painless Colonoscopy Patients · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05203276 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First People's Hospital of Lianyungang
- Last refreshed: 22 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05203276.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing